Royalty Rates for Pharmaceuticals & Biotechnology 6th Edition

Royalty Rates for Pharmaceuticals & Biotechnology 7th Edition- Coming Soon!

Order from ITI:

Price: $1950

This report is a tool that can be used to optimize the pricing of biotechnology and pharmaceutical intellectual property. The information in this resource is also useful for the valuation of patents and establishing damages for infringement litigation. The sixth edition of Royalty Rates for Pharmaceuticals & Biotechnology continues to focus on the royalty rates associated with biotechnology and pharmaceutical intellectual property transfers.

This report is organized into two parts. The first part covers the theory associated with deriving royalty rates. An overview of intellectual property value is provided along with seven methods that can be employed to derive royalty rates. The methods discussed are both qualitative and quantitative. Illustrative examples of each method discussed are provided.

The second part of this report presents detailed financial information about real world third-party transactions that center on the transfer of biotechnology and pharmaceutical intellectual property. The parties involved in the transactions are disclosed along with a description of the technology exchanged and all of the financial details that could be discovered. For this sixth edition we have emphasized the reporting of royalty rates and other financial compensation, associated with license agreements. We have updated and expanded information that was reported in past editions and conducted extensive research to expand the number of license agreements reported. The transaction information presented in this new edition has been collected from well-established sources believed to be reliable from September 1990 through December 2009.

Summarized below is the royalty rate data found throughout the License Agreement section of this book. Only royalty rates, presented as a percent of sales, are included in the graph below. For license agreements containing more than one rate, all rates are representing with equal weight in the graph.

GRAPH 1

Graph 1 clearly shows the majority of royalty rates are in the mid to low single digits.
In Graph 2, all license fees found in the License Agreement section of this report are presented.

GRAPH 2

VERY UNIQUE ASSETS
BUSINESS ENTERPRISE FRAMEWORK
DRIVING FORCES BEHIND ROYALTY RATES
SIMPLISTIC RULES OF THUMB
ROYALTY RATES AND INDUSTRY GUIDELINES
INFRINGEMENT DAMAGES ANALYSIS
GENERIC PRICING
COMPARABLE LICENSE TRANSACTIONS
INVESTMENT RATE OF RETURN ANALYSIS
DISCOUNTED CASH FLOW ANALYSIS
RISK ADJUSTED NET PRESENT VALUE
VALUATION USING THE RELIEF-FROM-ROYALTY METHOD
KEY COMPONENTS OF LICENSE AGREEMENTS

LICENSE AGREEMENTS

1,2-diphenylethanes, 1,3-diphenylpropanes and benzyl tetralins Adenocard Heart Disease Treatment Agriculture – Animal Health/Trilostane Agriculture – Golden Rice Alpha Interferon – Natural Alzheimer's Diagnostic Test Anesthetic Animal Health Products Anti-amyloid Peptide Platform Anti-infection Screening Process Anti-inflammatory – Topical Antifungal Agent – Amphotericin B Antifungal Antiviral Therapy Antiviral and Anti-infective Therapies Antiviral and Anti-infective Therapies Arginine Products Rheumatoid Arthritis Drug Humira Attention Deficit Hyperactivity Disorder Automated Cell Processing Instrument Automated Process Research Avinza BetaKine (TGF-beta-2) Bicifadine Blood Cell and Bone Marrow Production Blood Cell Therapy Blood Clot Formation Test Blood Plasma Volume Expander Cancer Treatment – Disodium Clodronate Cancer Treatment – DBD/Mitolactol Cancer Treatment OSI-774 Cancer Treatment – Oxygen Enhancement Cancer Treatment – huN901-DM1 Tumor-Activated Prodrug (TAP) Cancer – Tumor Treatment Cancer Treatment – Maytansinoid Tumor Cancer Treatment – Foscan Cancer Treatment – Gliadel Cancer Treatment – 9-Aminocamptothecin Cancer Treatment – Blood Cells Cancer Treatment – Oncolysin B Cancer Treatment - Ribonucleases Cancer Treatment - Vaccines Cancer Treatment – Radio Labeled Antibody Cancer Treatment – Carbohydrate Compounds Cardiovascular – Beta Blocker Cardiovascular – Beta Blocker Cardiovascular – Bextra™ Cardiovascular Generic Drug – ThromboClear Cartilage Regenerative Technology Catheter Technology cdkl Assay Coronary Drug-eluting Stent Cell Cultures Chimeric IgG1 antibodies Chromosome Analysis Technology Cochleates, Liposomes and Proteoliposomes Cold Remedy Cold Remedy Collagenase Ointment Consensus Interferon Contraceptive Contrast Agent – Intravenous Cough Medicine Cyclin Dependent Kinasc Assay Test Kit Cypress Stem Cells Cystic Fibrosis Treatment Cytomegalovirus Intravenous Treatment Deferrum® deferiprone Dermatology Diabetes Diagnostic Imagining Using Ligands Dietary Supplement – Botanical Diltiazem Heart Drug DNA Binding Invention DNA – PK Drug Delivery Drug Delivery – Topical Drug Delivery – Controlled Release Drug Development Technology Drug Development, Botanical-based EGF Fusion Protein Environmental Test Kit Epilepsy Treatment – ADCI EPO, Hepatitis B and IL-2 Estrogen Replacement Therapy Financing Research Gene Alteration Technology Gene Activation Technology Genetic Research Gene Sequencing Genetic Technology Genetic Abnormalities Test– Prenatal Gene Splicing Technology Genomics-based Drug Discovery Hepatitis A Vaccine Hepatitis B & C Treatment HIV Treatment – alpha interferon HIV Treatment – interferon-g HIV Treatment – (NNRTI) HIV Diagnosis and Treatment HIV and Hepatitis Vaccines HIV Vaccine Human Growth Hormone Humanized Antibody Humanized Monoclonal Antibody Humanization Antibody	Immune System Regulators – Cytokines Immunodeficiency Immunotoxin – MDX-RA Indiplon Influenza Drug Integrelin Drug Interferon Gamma-1b Interferon – Natural Living Cells Connective Tissue Lubrin® Mammary Cell Growth Inhibitor Michellamine B/Tropical Vine Leaves Microorganism Detection in Water Microsponge Delivery System Migraine Relief Monoclonal Antibodies Binding to TGF-B Monoclonal Antibody Technology Monoclonal Antibody 45-J Test Monoclonal Antibodies To Gram Negative Sepsis-Related Bacteria Naked DNA Technology Nanocrystalline Particles NASA Technology Nasal Vitamin B-12 Therapy Neurological Peptide Therapy Nifedipine Crystals Novasome Lipid Vesicles Encapsulation Nuclear Matrix Protein Technology Nucleic Acid Sequences for Detection Nucleic Acid Probe Technology Nucleic Acid Targeting Nucleic Acid Technologies Nutrition – Salt Alternative Obesity Therapy Opthalmic – Patent Formulation for Loteprednol Etabonate Oral Contraceptive Osteoporosis Compound 1-apiha-hydroxyvitamin D2 Oxygenation PEG Enhanced L-asparaginase Pain Therapy Pegylated Reagent Personal Care – Bioadhesive Delivery System Personal Care – Cosmetic Liposomal Personal Care – Facial Hair Treatment Personal Care – Hand Cleanser Personal Care - Kinetin™ Skin-Care Treatment Personal Care – Melanin Sunscreen Agent Personal Care – Moisturizers Personal Care – Moisturizers Personal Care – Mycrobicide Lotion Personal Care – Oral Treatment Personal Care – Serine Elastase Inhibitor Personal Care – Skin Barrier Repair Personal Care – Skin Care Moisturizers Personal Care – Topical Antiseptics Personal Care – Various Products Platinate HPMA Copolymer Photodynamic Therapy Polymerase Chain Reaction Technology Poly (ADP Ribose) Polymerase Diagnostic Assay Preeclampsia/Toxemia Diagnosis and Therapy Pro-Apolipoprotein A-I and Lipid Complexes Protein Secretion Technology Proteomics Technology Psychiatric And Psychotic Therapy Radynilel Hypoxic Tumor Cell Radiosensitizer Rapid Diagnostic Test RAS Human Protein/Rational Drug Design Retinoids Sarafem® Sexual Dysfunction Therapy Sleep Therapy – Nasal Administration Skin Technology - Polyactive Polymer Biomaterial Spirulina Stem-loop Vector Technology Stromal Derived Factor 1 (SDF-1) Peptide Agonists and Antagonists Tamiflu™ Telavancin™ – Antibotic Thalidomide Thalidomide Analogs Tissue Malignancy Treatments Thymidine Kinase Isoenzyme Diagnostics TGF-beta Transdermal Estrogen Patch Tropical Plants Ultrasound Contrast Agent Vaccines, gene-based Vaccine Research Virus Vaccines Wart Removal Products Water-Jel Sterile Burn Dressings Eli Lilly & Co. Experiences Compulsory License Royalty Rates
Strategic Alliances
Anti-cancer Compounds Anti-inflammatory Drug BB-882 Anti-inflammatory – Topical Antibody-based Inflammation Therapeutics Asthma Drug – Oral Administration Biochemical Technology Portfolio BPI – Human Protein Brain-derived Neurotrophic Factor Cancer Treatment – Clofarabine Cancer Therapy - NeoRx's Avicidin® Cardiovascular – Angina Therapy Cancer Therapy – Trentinoin (LF) Cell Adhesion Research Cell Adhesion Technology – LEC-CAM Central Nervous System Therapeutics Combinational Chemistry Corsevin M – Monoclonal Antibody Dermatology Treatments Dexfenfluraminel Anti-Obesity Drug Diabetes (Type II) Mellitus Drug Diagnostic Alliance Drug Delivery - Sustained Release Enzyme Inhibitors Erythronmycin Antibiotic Gene Database Gene Therapy Partnership Network Gene Transcription Drugs Human Gene Technology Hepatitis B and C Genetic Therapy	Hepatitis E Vaccine HIV Drugs Integrin-specific Compounds for Osteoporosis Intracellular Receptor Technology Kidney Disease Treatment Kidney Failure Treatment LYM-1 and LYM-2 Antibodies Monoclonal Antibody HA-lA/Centoxin Mycobutin/Rifabutin Nerve Repair NeuroCell Joint Venture Neurological Therapeutics Primatized Antibodies Primatized Anti-CD4 Antibodies Protease Inhibitors to Treat HIV and AIDS Psychotherapeutic Drugs Pulmonary Drug Delivery System Recombinant Human Inerlukin-twelve(rhIL-1 2) Rhenium Radiotherapy Ribozymes Stem Cell Proliferation Factor Yeast-based Screening Technology

GRAPH 1

GRAPH 2

Table of Contents

LICENSE AGREEMENTS